APA (7th ed.) Citation

PS, Y., V, C., DT, M., M, Z., & W, R. (2026). Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis. Advances in therapy, 43(6), 2795. https://doi.org/10.1007/s12325-026-03574-8

Chicago Style (17th ed.) Citation

PS, Yamauchi, Chow V, Mytych DT, Zhou M, and Radziszewski W. "Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis." Advances in Therapy 43, no. 6 (2026): 2795. https://doi.org/10.1007/s12325-026-03574-8.

MLA (9th ed.) Citation

PS, Yamauchi, et al. "Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis." Advances in Therapy, vol. 43, no. 6, 2026, p. 2795, https://doi.org/10.1007/s12325-026-03574-8.